Join to View Full Profile
4849 Calhoun RdHouston, TX 77204
Phone+1 832-842-8386
Are you Kevin W Garey?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 1 invite waiting! - Read the latest clinical news, personalized to your specialty.
Education & Training
University of Illinois at ChicagoResidency, 1998 - 2001
University at Buffalo, State University of New YorkPharmD, 1997
Publications & Presentations
PubMed
- 6 citationsClostridioides difficile ribotypes isolated from domestic environment and from patients in Bangladesh.Mohammad Aminul Islam, Nayel D. Kabir, M. Moniruzzaman, Khurshida Begum, Dilruba Ahmed
Anaerobe. 2019-04-01 - 9 citationsRidinilazole for the treatment of Clostridioides difficile infection.Travis J Carlson, Bradley T. Endres, Eugénie Bassères, Anne J Gonzales-Luna, Kevin W. Garey
Expert Opinion on Investigational Drugs. 2019-02-26 - 11 citationsEpidemic Clostridioides difficile Ribotype 027 Lineages: Comparisons of Texas Versus Worldwide Strains.Bradley T. Endres, Khurshida Begum, Hua Sun, Seth T. Walk, Ali Memariani
Open Forum Infectious Diseases. 2019-02-01
Grant Support
- Diversity Supplement: Decoding the clinical impact of the recent evolution of metronidazole resistance on Clostridium difficile infectionTEXAS A&M UNIVERSITY HEALTH SCIENCE CTR2018–2028
- Diversity Supplement: Decoding the clinical impact of the recent evolution of metronidazole resistance on Clostridium difficile infectionTEXAS A&M UNIVERSITY HEALTH SCIENCE CTR2018–2028
- Diversity Supplement: Decoding the clinical impact of the recent evolution of metronidazole resistance on Clostridium difficile infectionTEXAS A&M UNIVERSITY HEALTH SCIENCE CTR2018–2028
- Diversity Supplement: Decoding the clinical impact of the recent evolution of metronidazole resistance on Clostridium difficile infectionTEXAS A&M UNIVERSITY HEALTH SCIENCE CTR2018–2028
- Diversity Supplement: Decoding the clinical impact of the recent evolution of metronidazole resistance on Clostridium difficile infectionTEXAS A&M UNIVERSITY HEALTH SCIENCE CTR2018–2028
- Diversity Supplement: Decoding the clinical impact of the recent evolution of metronidazole resistance on Clostridium difficile infectionTEXAS A&M UNIVERSITY HEALTH SCIENCE CTR2018–2028
- Diversity Supplement: Decoding the clinical impact of the recent evolution of metronidazole resistance on Clostridium difficile infectionTEXAS A&M UNIVERSITY HEALTH SCIENCE CTR2018–2028
- Diversity Supplement: Decoding the clinical impact of the recent evolution of metronidazole resistance on Clostridium difficile infectionTEXAS A&M UNIVERSITY HEALTH SCIENCE CTR2018–2028
- Diversity Supplement: Decoding the clinical impact of the recent evolution of metronidazole resistance on Clostridium difficile infectionTEXAS A&M UNIVERSITY HEALTH SCIENCE CTR2018–2028
- Decoding the clinical impact of the recent evolution of metronidazole resistance on Clostridium difficile infection.TEXAS A&M UNIVERSITY HEALTH SCIENCE CTR2018–2028
- Diversity Supplement: Decoding the clinical impact of the recent evolution of metronidazole resistance on Clostridium difficile infectionTEXAS A&M UNIVERSITY HEALTH SCIENCE CTR2018–2028
- Diversity Supplement: Decoding the clinical impact of the recent evolution of metronidazole resistance on Clostridium difficile infectionTEXAS A&M UNIVERSITY HEALTH SCIENCE CTR2018–2028
- Vancomycin Susceptibility Measures to Evaluate C. difficile infection OutcomesUNIVERSITY OF HOUSTON2024–2025
- Vancomycin Susceptibility Measures to Evaluate C. difficile infection OutcomesUNIVERSITY OF HOUSTON2024–2025
- A Serological Assay for Neutralizing Antitoxin Response in Patients with Clostridioides difficile Infection (Phase II)FZATA, INC.2018–2025
